Literature DB >> 15152978

Applying a mixed-integer program to model re-screening women who test positive for C. trachomatis infection.

Guoyu Tao1, Bartholomew K Abban, Thomas L Gift, Guantao Chen, Kathleen L Irwin.   

Abstract

We proposed a mixed-integer program to model the management of C. trachomatis infections in women visiting publicly funded family planning clinics. We intended to maximize the number of infected women cured of C. trachomatis infections. The model incorporated screening, re-screening, and treatment options for three age groups with respective age-specific C. trachomatis infection and re-infection rates, two possible test assays, and two possible treatments. Our results showed the total budget had a great impact on the optimal strategy incorporating screening coverage, test selection, and treatment. At any budget level, the strategy that used a relatively small per-patient budget increase to re-screen all women who tested positive 6 months earlier always resulted in curing more infected women and more cost-saving than the strategy that was optimal under the condition of not including a re-screening option.

Entities:  

Mesh:

Year:  2004        PMID: 15152978     DOI: 10.1023/b:hcms.0000020653.31862.23

Source DB:  PubMed          Journal:  Health Care Manag Sci        ISSN: 1386-9620


  32 in total

1.  Practice patterns for the elicitation of sexual history, education, and counseling among providers of STD services: results from the gonorrhea community action project (GCAP).

Authors:  S S Bull; C Rietmeijer; J D Fortenberry; B Stoner; K Malotte; N VanDevanter; S E Middlestadt; E W Hook
Journal:  Sex Transm Dis       Date:  1999-11       Impact factor: 2.830

2.  Screening for chlamydial infection: recommendations and rationale.

Authors: 
Journal:  Am J Prev Med       Date:  2001-04       Impact factor: 5.043

3.  Optimal resource allocation for curing Chlamydia trachomatis infection among asymptomatic women at clinics operating on a fixed budget.

Authors:  Guoyu Tao; Thomas L Gift; Cathleen M Walsh; Kathleen L Irwin; William J Kassler
Journal:  Sex Transm Dis       Date:  2002-11       Impact factor: 2.830

4.  Findings from STD screening of adolescents and adults entering corrections facilities: implications for STD control strategies.

Authors:  Kristen J Mertz; Richard A Voigt; Kathleen Hutchins; William C Levine
Journal:  Sex Transm Dis       Date:  2002-12       Impact factor: 2.830

5.  Treating chlamydial infection: compliance versus cost.

Authors:  H H Handsfield; W E Stamm
Journal:  Sex Transm Dis       Date:  1998-01       Impact factor: 2.830

6.  Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women. A use-effectiveness study in public health settings.

Authors:  S D Hillis; F B Coles; B Litchfield; C M Black; B Mojica; K Schmitt; M E St Louis
Journal:  Sex Transm Dis       Date:  1998-01       Impact factor: 2.830

7.  Genital Chlamydia infections in sexually active female adolescents: do we really need to screen everyone?

Authors:  D J Mosure; S Berman; D Fine; S DeLisle; W Cates; J R Boring
Journal:  J Adolesc Health       Date:  1997-01       Impact factor: 5.012

8.  Asymptomatic sexually transmitted diseases: the case for screening.

Authors:  Thomas A Farley; Deborah A Cohen; Whitney Elkins
Journal:  Prev Med       Date:  2003-04       Impact factor: 4.018

9.  Chlamydia trachomatis infection in women: a need for universal screening in high prevalence populations?

Authors:  H S Weinstock; G A Bolan; R Kohn; C Balladares; A Back; G Oliva
Journal:  Am J Epidemiol       Date:  1992-01-01       Impact factor: 4.897

10.  Chlamydia test monitoring during therapy.

Authors:  A Cerin; L Grillner; E Persson
Journal:  Int J STD AIDS       Date:  1991 May-Jun       Impact factor: 1.359

View more
  1 in total

1.  Packaging health services when resources are limited: the example of a cervical cancer screening visit.

Authors:  Jane J Kim; Joshua A Salomon; Milton C Weinstein; Sue J Goldie
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.